title: Current concepts for the neurohormonal management of left ventricular dysfunction after myocardial infarction.
abstract: The importance of addressing neurohormonal activation in patients after a myocardial infarction is now well-appreciated. Inhibition of the renin-angiotensin-aldosterone axis and the sympathetic nervous system can result in improved cardiac function and survival. As we learn more about other systems, we should be able to realize further benefits. In particular, the roles of endothelin, matrix metalloproteinases, and cytokines in remodeling are being investigated, with the potential to result in better outcomes for patients.
authors.affiliation: University of Maryland School of Medicine, 22 South Greene Street, Baltimore, MD 21201, USA.
authors.forename: Keyur B
authors.initials: KB
authors.lastname: Shah
authors.forename: Stephen S
authors.initials: SS
authors.lastname: Gottlieb
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D065128:Endothelin Receptor Antagonists; D006801:Humans; D018836:Inflammation Mediators / Q000037:antagonists & inhibitors; D009203:Myocardial Infarction / Q000150:complications*; D016032:Randomized Controlled Trials as Topic; D012084:Renin-Angiotensin System / Q000187:drug effects; D013564:Sympathetic Nervous System / Q000187:drug effects; D018487:Ventricular Dysfunction, Left / Q000188:drug therapy* / Q000209:etiology
chemical_list: D000319:Adrenergic beta-Antagonists; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D065128:Endothelin Receptor Antagonists; D018836:Inflammation Mediators